Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA grants emergency use authorization to the Zero Contact COVID-19 test kit as a saliva-based diagnostic for at home use to detect COVID-19.- Vitagene

Written by | 11 May 2020

Vitagene has announced the availability of 50,000 FDA authorized at home Zero-Contact or Saliva-based COVID-19 test kits for use during the current public emergency to detect COVID-19. Vitagene… read more.

La Jolla Pharmaceutical Company to provide Giapreza (Angiotensin II) for emergency medical program in patients with septic shock due to COVID-19 at CHIREC Delta Hospital, Brussels, Belgium.

Written by | 11 May 2020

La Jolla Pharmaceutical Company announced that it is providing Giapreza (angiotensin II) for an emergency medical program in patients with septic shock due to COVID-19 at the Centre… read more.

Health Canada approves Real-Time Fluorescent RT-PCR Kit for detecting SARS-CoV-2.- BGI Genomics

Written by | 8 May 2020

BGI Genomics announced that its subsidiary BGI Americas Corporation has received authorization under Interim Order from Health Canada to supply its Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2… read more.

TAVO + Keytruda demonstrated 41% overall response rate and 36% complete response in a late-stage metastatic melanoma study featured in ‘Clinical Cancer Research’.- Oncosec Medical.

Written by | 8 May 2020

Oncosec Medical announced published data in Clinical Cancer Research that demonstrated its lead product candidate, TAVO (interleukin-12 or “IL-12” plasmid), in combination with the anti-PD-1 checkpoint inhibitor Keytruda… read more.

First participants dosed in phase I/II trial of BNT 162 vaccine to prevent COVID-19. Pfizer + BioNTech SE

Written by | 7 May 2020

Pfizer Inc. and BioNTech SE announced that the first participants have been dosed in the U.S. in the Phase 1/II clinical trial for the BNT 162 vaccine program… read more.

FDA grants Emergency Use Authorization for its Elecsys Anti-SARS-CoV-2 antibody test which is also available in markets accepting the CE mark.

Written by | 5 May 2020

Roche announced that the FDA has issued an Emergency Use Authorization (EUA) for its new Elecsys Anti-SARS-CoV-2 antibody test. The test is designed to help determine if a… read more.

Indomethacin in Covid-19

Written by | 4 May 2020

Article by Christine Clark Doctors in New York have been using indomethacin in the treatment of covid-19 for some time and have gathered valuable, albeit anecdotal, experience in… read more.

FDA grants emergency use authorization of remdesivir to treat COVID-19.

Written by | 3 May 2020

Gilead Sciences, Inc. announced that the FDA has granted emergency use authorization (EUA) for the investigational antiviral remdesivir to treat COVID-19. The EUA will facilitate broader use of… read more.

Rolling submission at EMA for remdesivir to treat coronavirus disease.- Gilead Sciences

Written by | 3 May 2020

EMA’s human medicines committee (CHMP) has started a ‘rolling review’ of data on the use of the investigational antiviral medicine remdesivir for the treatment of coronavirus disease (COVID-19)…. read more.

EU gives CE mark approval to SARS-CoV-2 (COVID-19) antibody microarray test as a diagnostic for COVID-19.- Quotient

Written by | 2 May 2020

Quotient announced that it has completed the process for declaring conformity to the essential requirements of the In Vitro Diagnostics Directive (IVDD 98/79/EC) and has CE marked its… read more.

NIAID Adaptive clinical trial shows remdesivir accelerates recovery from advanced COVID-19.

Written by | 1 May 2020

Hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received placebo, according to a preliminary data analysis from a randomized,… read more.

FDA guidance for Phase III B-SIMPLE 4 trial of SB 206 to treat molluscum contagiosum.- Novan Inc.

Written by | 1 May 2020

Novan, Inc.has announced that the Company has received meeting minutes from the April 1, 2020 Type C meeting with the FDA regarding SB 206 for the treatment of… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.